History of the University of North Carolina at Chapel Hill

Banking on Brilliance: George Acheampong Sets the Standard for Financial Thought Leadership

Retrieved on: 
금요일, 11월 3, 2023
Entrepreneurship, Quantitative Marketing and Economics, Bachelor, History of the University of North Carolina at Chapel Hill, Economics, Quality of life, Venture capital, University, Acheampong, Marketing

ATLANTA, Nov. 3, 2023 /PRNewswire/ -- George Acheampong, an influential figure in personal finance, wealth building, and entrepreneurship, is leaving an indelible mark on the financial industry.

Key Points: 
  • ATLANTA, Nov. 3, 2023 /PRNewswire/ -- George Acheampong, an influential figure in personal finance, wealth building, and entrepreneurship, is leaving an indelible mark on the financial industry.
  • Under his leadership, Capitalwize, LLC offers expert financial planning and investment management, enabling clients to make proactive, practical, and customized financial decisions.
  • To further his mission, Acheampong founded Melanin Money, home to the #1 Financial Club for Aspiring Melanin Millionaires.
  • The platform features a Financial Social Network, on-demand education, and financial accountability partners, providing crucial resources and guidance for informed financial choices.

FUBON by Angel Yeast: Professional Yeast Solution for Sustainable Nutrition in Farming

Retrieved on: 
수요일, 10월 4, 2023
Social responsibility, Love, Kasetsart University, Life, Digestion, Biotechnology, Immunity, Chapel Hill, Multimedia, Carbon, MOS, World Animal Day, Nutritional science, Biodiversity, Texas Tech University, Animal, Risk, University, History of the University of North Carolina at Chapel Hill, AGPS, Spray drying, Ecosystem, Health, Probiotic, Safety, Beer, Agriculture, Vaccine, Ghent University

FUBON by Angel Yeast is a global leader of yeast-based products for animal nutrition committed to pushing forward green, ecological farming leveraging cutting-edge yeast technologies, promoting environmental protection, and fulfilling social responsibility.

Key Points: 
  • FUBON by Angel Yeast is a global leader of yeast-based products for animal nutrition committed to pushing forward green, ecological farming leveraging cutting-edge yeast technologies, promoting environmental protection, and fulfilling social responsibility.
  • FUBON by Angel Yeast offers solutions that enhance animal digestion, boost immunity, and reduce antibiotic use, ensuring animal health and safety.
  • "FUBON by Angel Yeast aims to provide new solutions for the health of people and animals.
  • To learn more about Angel Animal Nutrition, please visit https://en.angelyeast.com/products/animal-nutrition.html
    View original content to download multimedia: https://www.prnewswire.com/news-releases/fubon-by-angel-yeast-profession...

Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment

Retrieved on: 
화요일, 8월 15, 2023
Technology, Health Technology, Software, Biotechnology, Other Health, Health, Pharmaceutical, Data Management, Artificial Intelligence, Seizure, Drug development, SLP, Clinical Pharmacology & Therapeutics, Lennox–Gastaut syndrome, Simulations Plus, QST, Chapel Hill, Liver injury, Dravet syndrome, Risk, Hepatotoxicity, Drug design, Incidence, Patient, Manuscript, University, History of the University of North Carolina at Chapel Hill, ALT, FDA, Therapy, VPA, Cannabidiol, Safety, Medical device, Dietary supplement, Pharmaceutical industry, CBD

CBD is an FDA-approved treatment for seizures in patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Key Points: 
  • CBD is an FDA-approved treatment for seizures in patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
  • During the pre-approval clinical trials, treatment with CBD was occasionally associated with elevation in blood levels of ALT, a marker of liver injury, but this was much more common in patients already receiving treatment with VPA for seizures.
  • To identify potential underlying mechanisms, researchers used DILIsym to predict ALT levels in simulated populations that were treated with CBD alone, treated with VPA alone, and then treated with VPA before they were treated with CBD.
  • DILIsym predicted dose-dependent ALT elevations for CBD treatment and ALT elevations for VPA treatment when each was given alone, but the combined VPA and CBD treatment protocol mimicking the clinical trials did not increase the incidence of ALT elevations relative to CBD treatment on its own.